Epithelial-stromal interactions play a critical role in tumor initiation and progression; cancer-associated stroma, but not normal stroma, is known to be tumor-promoting. However, the molecular signal used by epithelial cancer cells to reprogram normal stroma to a tumorigenic stroma is not known. Here, we present evidence to suggest that the chemokine growth-regulated oncogene 1 (Gro-1) may be one such signaling molecule. We showed that the expression of Gro-1 is activated by RAS and is vital for cell survival and the malignant transformation of ovarian epithelial cells. Surprisingly, we found that Gro-1 is a potent inducer of senescence in stromal fibroblasts and that this effect depends on functional p53. Senescent fibroblasts induced by Gro-1 can promote tumor growth whereas abrogation of senescence through immortalization results in loss of such tumor promoting activity. We also demonstrated that stromal fibroblasts adjacent to epithelial cancer cells are senescent in human ovarian cancer specimens and in heterografts from RAS-transformed human ovarian epithelial cells and ovarian cancer cells. Moreover, Gro-1 was expressed at significantly higher amounts in ovarian cancer than in normal tissues and was higher in serum samples from women with ovarian cancer than in serum from women without ovarian cancer. These findings provide strong evidence that RAS-induced Gro-1 can reprogram the stromal microenvironment through the induction of senescence of fibroblasts and thus can promote tumorigenesis. Therefore, Gro-1 may be a therapeutic target as well as a diagnostic marker in ovarian cancer.
D
evelopment of cancer involves the accumulation of multiple genetic changes, and many of these genetic changes have been successfully identified and modeled for various types of cancer. However, clinical epithelial tumors do not represent merely a clonal expansion of mutated epithelial cells but instead consist of a heterogeneous, complex mass composed of mutated epithelial cells, stromal fibroblasts, inflammatory cells, and blood vessels. Epithelial-stromal interactions are known to have an important role in cancer development (1) (2) (3) . As the predominant cells in the stroma, fibroblasts are responsible for the collaboration of stromal and tumorigenic epithelial cells. The stromal fibroblasts in cancer are morphologically and functionally different from those in normal stroma, and they are known to promote tumor growth or the transformation of epithelial cells (4, 5) . The molecular signals that epithelial cancer cells use to reprogram stromal cells, however, are poorly defined.
Cellular senescence or aging is a stable form of growth arrest that can be induced by a variety of stimuli, including overexpression of specific oncogenes (6) . Cellular senescence was first observed in tissue culture and described by Hayflick (7) as a process that can limit the life span of cells by reducing their proliferation (replicative senescence). Senescent cells have certain distinctive features. In culture, they appear morphologically flattened and enlarged; physiologically, they show elevated senescence-associated acidic ␤-galactosidase (SA-␤-gal) activity and the formation of senescenceassociated heterochromatic foci (8, 9) . Senescence can either restrict or promote tumor growth at the cellular level (6) . In the absence of a genetic mutation disabling the senescence pathway in epithelial cells, oncogenic activation (such as that produced by the RAS oncogene) will cause epithelial cells to become senescent and thereby restrict tumor growth; this mechanism was recently shown to be a bona fide mechanism for in vivo tumor suppression (10) (11) (12) (13) . In other circumstances, however, senescent cells can alter tissue structure and function and promote tumor formation, particularly when the senescence program in nearby epithelial cells is disabled (10) (11) (12) (13) (14) . It is suspected that the activation of an oncogene in epithelial cells transmits signals to nearby stromal cells, altering the properties of the stroma to become cancer-promoting (15) . However, little is known about the nature of such a signal or how it would prompt stromal cells to cooperate with epithelial cells in tumor development.
Chemokines (chemotactic cytokines) could conceivably mediate communication between epithelial and stromal cells in the tissue microenvironment. The chemokine growth-regulated oncogene 1 (Gro-1) was first identified in 1985 as an autostimulatory melanoma mitogen from the human malignant melanoma cell line Hs0294 (16) (17) (18) (19) . Gro-1-associated functions are regulated through both autocrine and paracrine pathways in which Gro-1 binds to CXCR2 receptors (20, 21) . Study of Gro-1 paracrine functions have focused on its chemotactic regulation of stromal cells, including neutrophils, in the tissue microenvironment (22) . Here, we show that Gro-1 is activated by RAS and is required for RAS-mediated transformation. We also show that Gro-1 is a critical mediator of the stromalepithelial interaction in tumor promotion through its induction of senescence in stromal fibroblasts.
Results

Overexpression of Gro-1 Induces Transformation of Ovarian Surface
Epithelial Cells. Our previous transformation of three immortalized ovarian surface epithelial cell lines with K-RAS V12 or H-RAS V12 (23) led to increased expression of chemokines and cytokines. IL-1␤, IL-8, and Gro-1 were the three most up-regulated cytokines, implying that they have important roles in RAS-mediated transformation. To determine which of these three cytokines is critical for RAS-mediated transformation, we introduced retroviral vectors expressing IL-1␤, IL-8, or Gro-1 into T29 and T80 cells, cell lines that are immortalized but nontumorigenic (24) (for details of the vector constructions, see Supporting Methods, which is published as supporting information on the PNAS web site). Gro-1, but not IL-1␤ or IL-8, induced tumor formation in six of six nude mice after s.c. implantation of the cells. Tumor growth began at Ϸ21 days in mice bearing T29Gro-1 cells and at 75 days in mice bearing T80Gro-1 cells (Fig. 1A) . Gro-1 expression in tumors derived from both cell lines was elevated relative to that of the parental cells (Fig. 1 A) .
Next, we evaluated the functional role of Gro-1 in tumorigenesis by delivering small interfering RNA (siRNA) to Gro-1 using retrovirus into T29H (HRAS V12 -transformed T29) cells, T29Gro-1 (Gro-1-transformed T29) cells, and ovarian cancer SKOV-3 cells. Tumor growth in nude mice was either completely blocked (in T29H, T29Gro-1) or markedly inhibited (by Ͼ70% in SKOV-3 cells) by siRNA to Gro-1 (Fig. 1B) and reduced Gro-1 expression levels in all cases as well (Fig. 7 , which is published as supporting information on the PNAS web site). Collectively, these findings suggest that Gro-1 is an oncogenic protein that is necessary for the malignant transformation of HRAS V12 -transformed ovarian surface epithelial cells and growth of naturally derived ovarian cancer cells.
Survival of RAS-Transformed Cells and Ovarian Cancer Cells Depends
in Part on Gro-1 Expression. We previously showed that RAStransformed cells depend on IL-1 and IL-8 for survival (23) . To examine whether Gro-1 is also required for cell survival, we treated RAS-transformed cells (T29H and T80H), and ovarian cancer cells (SKOV-3) with a monoclonal antibody against Gro-1 and assessed the effect on apoptosis. Blocking Gro-1 in this way markedly increased the percentage of apoptotic cells in each cell line. The level of apoptosis reaches the maximal level by 24 h of treatment and gradually decreases afterward (Fig. 2) . The ensuing decreases in proportions of apoptotic cells may have been due to increases in viable cells in the constant level of Gro-1. These results demonstrate that Gro-1 is required for the survival of RAS-transformed cells and ovarian cancer cells through inhibition of apoptosis.
Gro-1 Is a Potent Inducer of Senescence in Stromal Fibroblasts. To be a chemoattractant oncoprotein, Gro-1 probably functions in a paracrine manner by being secreted from cells, diffusing into the microenvironment, and interacting with receptors on nearby stromal fibroblasts. To determine the role of Gro-1 in this process, we first treated 1 ϫ 10 5 cells from two normal ovarian stromal fibroblast lines, NOF150 and NOF151, with 250 ng͞ml Gro-1 in serum-free medium. We found that the cells became enlarged and flattened, showing growth arrest and increased SA-␤-gal activity after 10 days of treatment ( Fig. 3 Ac, Ad, Ag, and Ah) as compared with cells grown in normal medium without Gro-1 ( Fig. 3 Aa, Ab, Ae, and Af ), cells cultured in serum-free medium, or cells treated with the same concentration of mouse IgG. Culturing these fibroblasts with conditioned medium from RAS-or Gro-1-transformed T29 cells also induced senescence of primary fibroblasts (data not shown), demonstrating that Gro-1 secreted from these cells, as well as exogenous Gro-1, can induce senescence. We also assessed cellular senescence by using two other markers, HP1␤ (9) and p16 INK4A . Gro-1 treatment of NOF151 cells led to expression of HP1␤ in granular foci and marked increases in cytoplasmic p16 INK4A levels ( Fig. 8 A and B , which is published as supporting information on the PNAS web site).
Gro-1-Induced Senescence of Fibroblasts Depends on Functional p53.
Next, to examine the mechanism of Gro-1-mediated senescence, we infected NOF150 fibroblasts with siRNA to p53 or with siRNA to p53 and together with ectopic expression of the catalytic subunit of human telomerase reverse transcriptase (hTERT) (25) and compared cellular senescence with that of parental cells by analyzing SA-␤-gal activity and p16
INK4A expression. Treatment of parental NOF150 cells with Gro-1 led to strong blue staining on day 10, demonstrating activation of cellular senescence by Gro-1, but disruption of p53 suppressed or eliminated this effect (Fig. 3Bd) . Fibroblasts immortalized by the introduction of p53siRNA and hTERT in particular completely lost the senescent response to Gro-1 (Fig. Bf) . Disruption of p53 also markedly attenuated p16
INK4A expression, particularly in the presence of hTERT (for further details, see Fig. 9 , which is published as supporting information on the PNAS web site). These results suggest that Gro-1 induces senescence through a p53-dependent pathway.
Senescent Fibroblasts Induced by Gro-1 are Tumor-Promoting. To assess whether senescent cells induced by Gro-1 can facilitate the transformation of human epithelial cells, we treated a human ovarian fibroblast cell culture (NOF137) and a human mammary fibroblast cell culture (HMFC207) with Gro-1 (250 ng͞ml for 10 days). The treated cells were mixed with T29 cells (an immortalized yet nontumorigenic cell line) in a 1:100 ratio and injected into nude mice. The Gro-1-treated fibroblasts induced larger tumors than did the untreated fibroblasts (Fig. 4 A and B) , indicating that senescent fibroblasts enhanced the malignant transformation of immortalized ovarian epithelial cells. Interestingly, normal fibroblasts treated with Gro-1 and injected T29 cells also showed modest tumorigenesis, perhaps because of the accumulation of a few senescent fibroblasts during tissue culture, whereas T29 cells and fibroblast cells alone showed no tumor growth.
To further demonstrate that senescence of fibroblasts is required for tumor growth, we abrogated the senescence program through consecutive introduction of p53 siRNA and hTERT into the normal ovarian fibroblast NOF151 cell line to achieve immortalization as described recently (25) . We also introduced Gro-1 cDNA into these IF151 cells and injected the cells with T29 cells into nude mice. As shown in Fig. 4C , The immortalized ovarian fibroblasts (IF151) did not induce tumor growth of the T29 cells, but the immortalized IF151 cells that overexpressed Gro-1 (IF151-Gro-1) markedly stimulated tumor in the presence of Gro-1 was determined for the primary ovarian fibroblast line NOF150, NOF150 cells infected with retrovirus expressing p53siRNA (NOF150͞ p53i), and immortalized NOF150 fibroblasts infected with retrovirus expressing p53siRNA and with hTERT. Cells were treated with either Gro-1 or mouse IgG as described for Fig. 2 . Only the parental NOF150 cells showed strong blue staining, indicating senescence, after treatment with Gro-1. P2 and P21, passage number 2 and 21, respectively. growth of the T29 cells (Fig. 4C) . Thus, abrogation of senescent program in these fibroblasts through immortalization leads a loss of tumor-promoting activity. However, tumor-promoting ability can be regained through ectopic expression of Gro-1 in the immortalized cells, most likely through the induction of senescence of nearby murine fibroblasts, thereby creating a tumorprone microenvironment.
Fibroblasts Adjacent to Epithelial Ovarian Cancer Cells Are Senescent.
Although recent studies provide in vivo evidence that senescence is a bona fide tumor suppression mechanism in epithelial cells (10) (11) (12) (13) , it is unknown whether stromal fibroblasts associated with cancers are senescent in vivo. We reasoned that if senescent fibroblasts contribute to tumor promotion, we would detect them in or near human tumor specimens. To test this possibility, we examined the activity of SA-␤-gal and the expression of p16 INK4A , HP1␤, and Ki-67 (a marker of proliferation) in 44 frozen ovarian specimens, including both normal and tumor tissues. Many fibroblasts, particularly those near cancerous epithelial cells in ovarian carcinomas, showed marked positive staining for SA-␤-gal and p16 INK4A compared with normal ovarian tissue (Fig. 5 Aa and Ab). Only malignant epithelial cells showed Ki-67 staining (Fig. 5Ac) . HP1␤ staining was also strongly positive in the nuclei of fibroblasts in ovarian carcinoma tissues (Fig. 5B) . Strong staining for SA-␤-gal, p16 INK4A , and HP1␤ in fibroblasts was observed in 26 of 31 ovarian carcinoma tissues, whereas weak staining was found in two of seven borderline tumor samples. None of three cysts and three normal ovarian tissues showed staining for these markers. We further found positive staining for SA-␤-gal in xenograft tumor tissues from mice injected with T29Gro-1, T29H, or SKOV-3 cells (Fig. 5C ). Collectively, these results demonstrate that cancer-associated fibroblasts are senescent not only in human ovarian cancer but also in heterografts of ovarian tumors from nude mice.
On the basis of these findings, we hypothesized that cancerassociated fibroblasts would have high levels of Gro-1 and would promote the development of ovarian epithelial cancer. To test this hypothesis, we isolated five cancer-associated fibroblast cell lines from ovarian cancer tissues and five normal ovarian fibroblast cell lines. The normal ovarian fibroblasts grew faster in culture than did the cancer-associated fibroblasts (Fig. 6A) . However, cancerassociated fibroblasts were more potent stimulators of tumorigenicity of immortalized T29 cells injected s.c. in nude mice (Fig. 6B) . We also found that Gro-1 levels were significantly higher in the two cancer-associated fibroblast cell lines (CAF-143 and CAF145) than in the normal fibroblasts (Fig. 6C) . These findings suggest that the tumor-promoting ability of cancer-associated fibroblasts result at least in part to Gro-1-induced senescence of those fibroblasts.
Gro-1 Levels Are Increased in Serum and Ovarian Tissue Samples of
Women with Ovarian Cancer. To determine whether the senescence of fibroblasts in ovarian cancer is associated with an increase in Gro-1 secretion into serum, we tested Gro-1 levels in serum samples from 10 patients with ovarian cancer and from eight normal control subjects. We found that Gro-1 concentrations in the samples from women with cancer were elevated (mean, 125 ng͞ml) compared with those of the control subjects (40 ng͞ml) (P Ͻ 0.0001). Finally, we quantitatively analyzed and compared Gro-1 expression in epithelial cancer cells and stromal fibroblasts from 441 samples of ovarian cancer tissue microarray by immunohistochemical staining. The level of Gro-1 expression was relatively low in normal ovarian surface epithelial cells, fibroblasts, and cyst epithelial cells, but was markedly increased in ovarian epithelial cancer and stroma (Fig.  6E) . These findings imply that the secretion of Gro-1 into human blood and stroma is associated with ovarian cancer.
Discussion
Ovarian cancer is most lethal form of cancer among women in the United States, its symptoms are usually nonspecific until abdominal distension by ascites or large tumor masses becomes apparent. The RAS gene family has been implicated in human ovarian cancer as well as other epithelial cancers in humans. KRAS mutations have been found in benign and invasive mucinous ovarian cancers as well as nonmucinous ovarian tumors (26) (27) (28) (29) , both low-grade and serous carcinomas of low malignant potential often show high frequencies of mutations in K-ras and its downstream effector BRAF (30, 31) . Specifically, mutations in KRAS and BRAF together were detected in 68% of low-grade serous carcinomas and 61% of borderline serous tumors, indicating the importance of the K-ras pathway in these types of tumors. We recently demonstrated that high H-RAS protein levels in the absence of RAS mutations were critical for the ability of human ovarian cancer cells to form tumors (32) . In addition to RAS, other growth factors, such as lysophosphatidic acid, a glycerol backbone phospholipids mediator found in serum and ascites sample from women with ovarian cancer, can also activate Gro-1 expression (33) . These data suggest that both RAS and Gro-1 are key signaling molecules regulating ovarian tumorigenesis.
The interaction between epithelial cancer cells and stromal cells may be especially important in the development of various epithelial cancers, including breast cancer, colon cancer, prostate cancer, and glioma (34) (35) (36) (37) , and in aging (3, (38) (39) (40) . Some studies have shown that the interaction of ovarian cancer epithelial cells and stromal cells stimulates the progression of ovarian epithelial cancers (41, 42) . Fibroblast senescence has been linked with prostate cancer in humans and aging in baboons (43, 44) . Other studies have shown that cancer-associated fibroblast, but normal fibroblasts can promote the transformation of epithelial cells (4, 5, 34) . Here, we show that Gro-1 induces the senescence of fibroblasts to alter tumor microenvironments, which in turn promotes the malignant transformation of epithelial cells.
Senescence induced by RAS serves as a potent tumor suppressor mechanism, restricting the growth of cells that have intact senescence-responsive pathways. Here, we provide evidence that RAS can also send Gro-1 as a molecular signal to the stromal microenvironment, reprogramming it through the induction of senescence and thereby promoting tumor growth or malignant transformation of immortalized epithelial cells. Our finding that the silencing of Gro-1 by siRNA eliminated the RAS-induced transformation of human ovarian epithelial cells (T29) suggests that RAS-induced transformation may largely depend on activation of Gro-1. Indeed, Gro-1 seems to be a key molecular link among RAS-mediated transformation, inhibition of apoptosis, senescence of stromal fibroblasts, and tumor progression. Thus, Gro-1 may be the longsought molecular signal that is activated by oncogenes and other extracellular oncogenic signals in epithelial cells and sent to the microenvironment to synchronize the stroma with epithelial cells and thereby promote tumor development. Thus, Gro-1 may be a novel therapeutic target for tumor with mutated RAS oncogene; it may also be a novel diagnostic marker for these tumors.
Methods
Tissue Culture, Cell Lines, Isolation of Normal and Cancer-Associated Ovarian Fibroblasts, and Retroviral Infection. Media used to culture normal and tumor-associated ovarian fibroblasts, T29 and T80 cells, Phoenix amphotropic retroviral packaging cells, SKOV-3 cells, and the transformed T29Gro-1, T29IL-1␤, T29IL-8, T29H, T80Gro-1, T80IL-1␤, T80IL-8, and T80H cells are described elsewhere (23, 32, 45) . Normal ovarian and cancer-associated fibroblasts were collected and isolated with informed consent from the donors according to a protocol approved by The University of Texas M. D. Anderson Cancer Institutional Review Board.
SA-␤-Gal. Staining for SA-␤-gal was done according to previously published protocols (8) . Immunohistochemical Staining. Immunohistochemical staining for p16 INK4A , Ki-67, and Gro-1 was done by using the avidin-biotinperoxidase methods as described elsewhere (46, 47) . The primary antibodies against p16 INK4A (CM020B, 1:100) and that for Ki-67 (CP249B, 1:100) were from Biocare Medical (Concord, CA); Gro-1 was from R & D Systems (AF275, 1:500).
Western Blotting. Western blot analyses were done as described (23, 45) . The primary Gro-1 antibody was from R & D Systems (MAB275, 1:1,000 dilution). The secondary antibody against mouse IgG (RPN4201) conjugated with horseradish peroxidase was from Amersham Bioscience (Piscataway, NJ). Enhanced chemiluminescence reagents (Amersham Pharmacia, Piscataway, NJ) were used in a 1:1 ratio, in exposure times of 1-5 min.
Apoptosis Assay. Apoptotic cells were assessed as described (23) .
Determination of in Vivo Tumorigenicity. To determine cell tumorigenicity in vivo, 5 ϫ 10 6 T29, T29Gro-1, T29IL-1␤, T29IL-8, T80, T80Gro-1, T80IL-1␤, T80IL-8, T29Gro-1͞Gro-1siRNA, or T29H͞Gro-1siRNA cells; or 1 ϫ 10 6 SKOV-3͞U6 or SKOV-3͞ Gro-1siRNA cells were harvested by trypsinization, washed twice with PBS, resuspended in 0.15 ml of saline, and injected s.c. (T29, T80, and SKOV-3 and their derivatives), into 4-to 6-week-old BALB͞c athymic nude mice (BALB͞cAnNCr-nu͞ nu, National Institutes of Health). The mice were kept in a pathogen-free environment and checked every 2 days for 5 months. Mice were killed when tumors reached 1.5 cm in diameter. To compare the tumor volume and cell number, Student's t test or one-way analysis of variance was used as appropriate. A P value of Ͻ0.05 was considered statistically significant.
Gro-1 Treatment of Primary Fibroblasts and Detection of Senescence
Markers. Primary cultured fibroblasts (1 ϫ 10 5 ) were seeded in chambered slides and treated with Gro-1 (250 ng͞ml) in serum-free medium for 7-10 days; the control assays were performed in the same medium by using mouse IgG (250 ng͞ml), or without antibodies. Immunofluorescence staining was done according to a published protocol (48) and then incubated with antibodies to HP1␤ (MAB3448, 1:2,000; Chemicon International, Temecala, CA) or p16 INK4A (CM020B, 1:1,000; Biocare Medical) and goat anti-actin (I-19, 1:1,000, Santa Cruz Biotechnology, Santa Cruz, CA) for 1 h at 37°C, followed by washing with PBS͞Tween 20 (0.1%). Secondary antibodies (Jackson ImmunoResearch Laboratory, West Grove, CA) against mouse IgG conjugated with fluorescein isothioscyanate (715-095-150; 1:1,000) or goat IgG (705-075-003; 1:1,000) conjugated with Texas red and To-Pro-3 (1:1,000; Molecular Probes, Eugene, OR) were then applied to the cells for 30 min at 37°C, after which slides were washed with PBS͞Tween 20 and mounted with anti-fade reagent (Molecular Probes). Slides were examined and photographed with an Olympus FV500 confocal fluorescence microscope. For HP1␤ staining of frozen sections, frozen tissues were freshly sectioned and fixed with 2% formaldehyde and 0.2% glutaraldehyde in PBS for 4 min at room temperature. Primary and secondary antibodies were applied to the slides as described above, but 4Ј,6-diamidino-2-phenylindole was used as the nuclear dye instead of To-Pro-3. Cells were visualized and photographed under fluorescence microscopy.
Stromal Fibroblasts and T29 Cells and Tumor Growth. Normal ovarian fibroblasts NOF137, NOF150, and NOF151 and normal human mammary fibroblast cells HMFC207 (1 ϫ 10 5 ) were treated with Gro-1 at a concentration of 250 ng͞ml for 10 days and then mixed with preneoplastic T29 cells (5 ϫ 10 6 ) in a ratio of 1:100 and and cocultured for 12 h before their bilateral s.c. injection into nude mice. The immortalized fibroblast cell lines IF-151 were generated by introducing retrovirus expressing siRNA against p53 and by ectopically expressing of the catalytic subunit of telomerase (hTERT) as described elsewhere (25) . IF151-Gro-1 cells were generated by infecting the IF151 cells with retrovirus expressing Gro-1. Like normal fibroblasts, the modified fibroblasts were then mixed with T29 cells at a ratio of 1:100. Cancer-associated fibroblasts or normal ovarian fibroblasts were mixed with T29 cells at that ratio of 1:100 and cultured for 12 h before being injected. Tumor burden was measured and recorded every other day.
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